• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

byTeddy Guo
December 23, 2020
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click to read the study in JAMA Network Open

RELATED REPORTS

Trastuzumab emtansine improves outcomes in residual HER2-positive breast cancer

#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Tags: carboplatincost-effectivedocetaxelERBB2-positive breast cancerHER2-positive breast cancerpaclitaxelpertuzumabtrastuzumabtrastuzumab emtansine
Previous Post

#Visual Abstract: Special Report: Vaccines in Development Part 1: Pfizer/BioNTech vaccine first to receive emergency use authorization

Next Post

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

RelatedReports

Exercise associated with decreased breast cancer risk
Oncology

Trastuzumab emtansine improves outcomes in residual HER2-positive breast cancer

March 7, 2025
#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer
StudyGraphics

#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer

February 7, 2025
Adjuvant radiotherapy reduces recurrence of ductal carcinoma; no effect on long-term prognosis
Chronic Disease

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

January 27, 2025
#VisualAbstract: Increased Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer Relative to Trastuzumab Alone
StudyGraphics

#VisualAbstract: Increased Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer Relative to Trastuzumab Alone

January 24, 2025
Next Post
Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

#VisualAbstract: Adjunctive methylprednisolone treatment for hepatitis B acute-on-chronic liver failure associated with increased survival

#VisualAbstract: Enteral water-soluble vitamin A in extremely preterm infants does not reduce severity of bronchopulmonary dysplasia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nerandomilast slows FVC decline in progressive pulmonary fibrosis
  • 2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
  • 2 Minute Medicine Rewind July 7, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.